Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?

详细信息    查看全文

• 作者：Jorge Romero ; Samuel H. Baldinger…
• 关键词：Methadone ; Torsades de pointes ; Prolonged QT
• 刊名：Journal of Interventional Cardiac Electrophysiology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：45
• 期：1
• 页码：37-45
• 全文大小：440 KB
• 参考文献：1.Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350(10), 1013–1022.CrossRef PubMed
  2.Haverkamp, W., et al. (2000). The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. European Heart Journal, 21(15), 1216–1231.CrossRef PubMed
  3.Luo, S., et al. (2004). A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. Journal of Electrocardiology, 37(Suppl), 81–90.CrossRef PubMed
  4.Torigoe, S., et al. (1992). p53 gene mutation in primary human renal cell carcinoma. Oncology Research, 4(11–12), 467–472.PubMed
  5.Antzelevitch, C., et al. (1996). Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. Journal of the American College of Cardiology, 28(7), 1836–1848.CrossRef PubMed
  6.Fingerhut, L. A. (2008). National Center for Health Statistics. Increases in poisoning and methadone-related deaths: United States, 1999–2005.
  7.Substance Abuse and Mental Health Services Administration, National Survey of Substance Abuse Treatment Services (N-SSATS) 2013. (2014). Data on substance abuse treatment facilities. BHSIS Series S-73, HHS Publication No. (SMA) 14–489. Rockville, MD: Substance Abuse and Mental Health Services Administration.
  8.Substance Abuse and Mental Health Services Administration, 2011 Opioid Treatment Program Survey: data on substance abuse treatment facilities with OTPs. (2013). BHSIS Series S-65, HHS. Publication No. (SMA) 14–4807. Rockville, MD: Substance Abuse and Mental Health Services. Administration.
  9.Rautaharju, P. M., Rautaharju, P. M., et al. (2009). AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. Journal of the American College of Cardiology, 53(11), 982–991.CrossRef PubMed
  10.Brown, R., et al. (2004). Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. Postgraduate Medical Journal, 80(949), 654–659.PubMedCentral CrossRef PubMed
  11.Sani, M. U., & Okeahialam, B. N. (2005). QTc interval prolongation in patients with HIV and AIDS. Journal of the National Medical Association, 97(12), 1657–1661.PubMedCentral PubMed
  12.Vallecillo, G., et al. (2013). Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy. Clinical Infectious Diseases, 57(8), 1189–1194.CrossRef PubMed
  13.General Accountability Office. Methadone-associated overdose deaths: factors contributing to increased deaths and efforts to prevent them. Available at: http://​www.​gao.​gov/​products/​GAO-09-341 . Accessed june 2014
  14.Haigney, M. C. (2011). First, do no harm: QT interval screening in methadone maintenance treatment. Journal of Addictive Diseases, 30(4), 309–312.CrossRef PubMed
  15.Rosemont Pharmaceuticals Limited. Methadone hydrochloride DTF 1 mg/1 ml oral solution. Available at: http://​xpil.​medicines.​org.​uk/​ViewPil.​aspx?​DocID=​22767 . .
  16.Andrews, C. M., et al. (2009). Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiology Journal, 16(3), 210–217.PubMed
  17.Hall, A. J., et al. (2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA, 300(22), 2613–2620.CrossRef PubMed
  18.Verispan. (2008). Food and Drug Administration, Center for Drug Evaluation and Research. Verispan Total Patient Tracker, Year 2007.
  19.Sims, S. A., Snow, L. A., & Porucznik, C. A. (2007). Surveillance of methadone-related adverse drug events using multiple public health data sources. Journal of Biomedical Informatics, 40(4), 382–389.CrossRef PubMed
  20.Grilo, L. S., Carrupt, P. A., & Abriel, H. (2010). Stereoselective inhibition of the hERG1 potassium channel. Frontiers in Pharmacology, 1, 137.PubMedCentral CrossRef PubMed
  21.Katchman, A. N., et al. (2002). Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. Journal of Pharmacol and Experimental Therapeutics, 303(2), 688–694.CrossRef
  22.Auriacombe, M., Franques, P., & Tignol, J. (2001). Deaths attributable to methadone vs buprenorphine in France. JAMA, 285(1), 45.CrossRef PubMed
  23.Johnson, R. E., et al. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine, 343(18), 1290–1297.CrossRef PubMed
  24.Lintzeris, N., et al. (2002). A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction, 97(11), 1395–1404.CrossRef PubMed
  25.Wedam, E. F., et al. (2007). QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Archives of Internal Medicine, 167(22), 2469–2475.CrossRef PubMed
  26.Deamer, R. L., et al. (2001). Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). Journal of Addictive Diseases, 20(4), 7–14.CrossRef PubMed
  27.Prendergast, M. L., et al. (1995). Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction. Journal of Psychoactive Drugs, 27(3), 239–247.CrossRef PubMed
  28.Priori, S. G., et al. (2003). Risk stratification in the long-QT syndrome. New England Journal of Medicine, 348(19), 1866–1874.CrossRef PubMed
  29.Benoit, S. R., et al. (2005). Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. European Journal of Cardiovascular Prevention and Rehabilitation, 12(4), 363–368.CrossRef PubMed
  30.Sanguinetti, M. C., et al. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell, 81(2), 299–307.CrossRef PubMed
  31.Milne, J. R., et al. (1984). Class 1 antiarrhythmic drugs—characteristic electrocardiographic differences when assessed by atrial and ventricular pacing. European Heart Journal, 5(2), 99–107.PubMed
  32.Yang, P., et al. (2002). Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation, 105(16), 1943–1948.CrossRef PubMed
  33.Newton-Cheh, C., et al. (2007). Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation, 116(10), 1128–1136.CrossRef PubMed
  34.Makita, N., et al. (2002). Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation, 106(10), 1269–1274.CrossRef PubMed
  35.Priori, S. G., et al. (1999). Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation, 99(4), 518–528.CrossRef PubMed
  36.Priori, S. G., Napolitano, C., & Schwartz, P. J. (1999). Low penetrance in the long-QT syndrome: clinical impact. Circulation, 99(4), 529–533.CrossRef PubMed
  37.Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract, 3(1), 45–50.PubMedCentral CrossRef PubMed
  38.Mujtaba, S., Romero, J., & Taub, C. C. (2013). Methadone, QTc prolongation and torsades de pointes: current concepts, management and a hidden twist in the tale? J Cardiovasc Dis Res, 4(4), 229–235.PubMedCentral PubMed
  39.Krantz, M. J., Garcia, J. A., & Mehler, P. S. (2005). Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy, 25(4), 611–614.CrossRef PubMed
  
• 作者单位：Jorge Romero (1) (2)
  Samuel H. Baldinger (2)
  David Goodman-Meza (1)
  Krysthel Engstrom (1)
  Carolina R. Valencia (1)
  Anjani Golive (1)
  Francisco Medrano (1)
  Sabarivinoth Rangasamy (1)
  Mohammed Makkiya (1)
  John D. Fisher (1)
  Jay Gross (1)
  Andrew Krumerman (1)
  Soo Kim (1)
  Mario J. Garcia (1)
  Luigi Di Biase (1)
  Kevin J Ferrick (1)
  
  1. Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Silver Zone, 10467, Bronx, NY, USA
  2. Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  
• 出版者：Springer Netherlands
• ISSN：1572-8595

文摘

Background Although it has been well established that methadone use can result in prolonged QTc/torsades de pointes (TdP) and has been labeled as one of the main drugs that cause TdP, it is still prescribed indiscriminately, and several cases of methadone-associated TdP have been seen in our community.